• Ionis Pharmaceuticals published a medical research presentation on olezarsen, an APOC3-targeting antisense drug, in severe hypertriglyceridemia.
• Pooled Phase 3 CORE-TIMI 72a and CORE2-TIMI 72b data showed an 85% reduction in acute pancreatitis events vs placebo (RR 0.15; p<0.001).
• Absolute risk reduction in total events was 5.2%, implying an NNT of 20 over 1 year.
• Benefit was reported as consistent across baseline triglyceride levels and prior pancreatitis status, with the highest absolute gains in higher-risk patients.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ionis Pharmaceuticals Inc. published the original content used to generate this news brief on June 14, 2026, and is solely responsible for the information contained therein.